Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
alpha receptor antagonist
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Prostatic Hypertrophy, Benign
1 trial -
anti CD19 CAR NK cells
The First People's Hospital of Lianyungang
Antisynthetase Syndrome
1 trial -
anti-CD19 CAR-T
The First People's Hospital of Lianyungang
B-cell Adult Acute Lymphoblastic Leukemia
1 trial -
anti-CD19 allo-CAR-T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed Adult ALL
1 trial -
anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells
The First People's Hospital of Lianyungang
Relapsed/refractory Lymphoma
1 trial -
autologous decidual-like NK cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Abortion, Habitual
1 trial -
blinatumomab and auto-HSCT "sandwich " strategy
The First People's Hospital of Lianyungang
B-cell Acute Lymphoblastic Leukemia
1 trial -
bronchial basal cells
The First People's Hospital of Lianyungang
Chronic Respiratory Disease
1 trial -
cisplatin oxaliplatin tegafur
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
dendritic cell
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Recurrent Ovarian Cancer
1 trial -
dexlansoprazole injection
The First People's Hospital of Lianyungang
Safety Issues
1 trial -
domestic polysaccharide superparamagnetic iron oxide nanoparticle
The First People's Hospital of Lianyungang
Chronic Kidney Diseases
1 trial -
fRPE cells
The First People's Hospital of Lianyungang
Age Related Macular Degeneration
1 trial -
hCD19.IL15.CAR-iNKT
The First People's Hospital of Lianyungang
Acute Lymphoblastic Leukemia
1 trial -
hUCB
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Ischemic Stroke
1 trial -
haploid allogeneic NK cell therapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Myeloid Leukemia
1 trial -
high-fat diet groupοΌAD16 20mgοΌ
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Alzheimer Disease
1 trial -
human HER2-targeted CAR-M cells
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
imatinib mesylate
Children's Hospital of Fudan University
Leukemia
1 trial -
iridoid enriched mixed fruit beverage
International Peace Maternity and Child Health Hospital
Oxidative Stress
1 trial -
mesenchymal stem cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral Vascular Disease
1 trial -
narfurine hydrochloride orally disintegrating tablets
The First People's Hospital of Lianyungang
Improvement of Pruritus in Hemodialysis Patients
1 trial -
oncolytic virus (OVV-01) injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Neoplasms
1 trial -
oxytocin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Healthy
6 trials
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources